Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III clinical trial of fixed dose combination Cefepime / AAI101

Trial Profile

A phase III clinical trial of fixed dose combination Cefepime / AAI101

Planning
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2018

At a glance

  • Drugs AAI101/cefepime (Primary)
  • Indications Gram-negative infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Aug 2018 According to an Allecra Therapeutics media release, trial will be executed in 19 countries and in 114 trial sites, with more than 1,000 patients involved.
    • 23 Aug 2018 According to an Allecra Therapeutics media release, company is ready to commence this study.
    • 16 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top